Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.73 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 10/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21759066 | 0.80 | ALDH1A1 (0.71) | PRMT5WDR77ALDH1A1MEN1KMT2A | |
| SCHEMBL21759060 | 0.79 | ALDH1A1 (0.54) | PRMT5WDR77ALDH1A1MEN1KMT2A | |
| SCHEMBL19648494 | 0.78 | MEN1 (0.57) | PRMT5WDR77ALDH1A1MEN1KMT2A | |
| SCHEMBL18219844 | 0.77 | HRH3 (0.59) | PRMT5WDR77ALDH1A1MEN1KMT2A | |
| SCHEMBL22830949 | 0.77 | MEN1 (1.00) | PRMT5WDR77ALDH1A1MEN1KMT2A | |
| SCHEMBL28704316 | 0.74 | MEN1 (0.65) | PRMT5WDR77ALDH1A1MEN1KMT2A | |
| SCHEMBL28685627 | 0.74 | MEN1 (0.65) | PRMT5WDR77ALDH1A1MEN1KMT2A | |
| SCHEMBL28685631 | 0.74 | MEN1 (0.65) | PRMT5WDR77ALDH1A1MEN1KMT2A | |
| SCHEMBL21759103 | 0.74 | MEN1 (0.54) | PRMT5WDR77ALDH1A1MEN1KMT2A | |
| SCHEMBL5555860 | 0.74 | BCHE (0.65) | MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673853-B2 | Small molecule AMPK activators | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673853-B2 | Small molecule AMPK activators | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220153685-A1 | SMALL MOLECULE AMPK ACTIVATORS | THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS TECHNOLOGY TRANSFER PROGRAM (10P9TT) | 2022-05-19 | — | — | US | disclosed |
| US-11040935-B2 | Small molecule AMPK activators | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200062693-A1 | SMALL MOLECULE AMPK ACTIVATORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-02-27 | — | — | US | disclosed |
| WO-2018067685-A1 | SMALL MOLECULE AMPK ACTIVATORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673853-B2 | Small molecule AMPK activators | PRKAG1, PRKAG2, PRKAA1 | PRMT5 1622/4885WDR77 272/4885ALDH1A1 2770/4885 |
| US-20220153685-A1 | SMALL MOLECULE AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | PRMT5 1622/4885WDR77 272/4885ALDH1A1 2770/4885 |
| US-11040935-B2 | Small molecule AMPK activators | PRKAG1, PRKAG2, PRKAA1 | PRMT5 1622/4885WDR77 272/4885ALDH1A1 2770/4885 |
| US-20200062693-A1 | SMALL MOLECULE AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | PRMT5 1622/4885WDR77 272/4885ALDH1A1 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.